<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680365</url>
  </required_header>
  <id_info>
    <org_study_id>Jett 0001</org_study_id>
    <nct_id>NCT03680365</nct_id>
  </id_info>
  <brief_title>Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families</brief_title>
  <official_title>Your Voice; Impact of DMD. A Qualitative Assessment of the Impact of DMD on the Lives of Families</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jett Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Engage Health, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hyman, Phelps, &amp; McNamara, P.C.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ryans Quest Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michaels Cause Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solid Biosciences, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Santhera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Italfarmaco</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catabasis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wave Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capricor Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NS Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jett Foundation, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to improve the understanding of the treatment goals that a
      person with Duchenne Muscular Dystrophy (DMD) or the caregiver may be most interested in,
      based on the severity of the person's disease. Data will be collected by online survey when
      the participant accepts the study invitation (&quot;RSVP questionnaire&quot;) and telephone interview
      on the functional burden and self-identified treatment goals from the perspective of people
      with DMD and their caregivers. Interviews will be analyzed to help identify things important
      to Duchenne families to measure in clinical trials and to inform the selection of key
      concepts of interest and development of future clinical outcome measures, including observer
      reported outcomes/patient reported outcomes. The study will be conducted in the United States
      and will enroll between 45 and 120 participants 11 years or older living with DMD as well as
      their caregivers. The time commitment for the online survey and the telephone interview is
      about one hour. It is anticipated that the entire study will be completed within one year.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Actual">March 15, 2019</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient/Parent Interview Assessing Treatment Needs</measure>
    <time_frame>1 year</time_frame>
    <description>In this non-interventional study, up to 120 patients/parents will participate in an online survey designed to determine the patient's functional category; ambulatory, transitional, or non-ambulatory. 15 patients from each functional category will be interviewed to gather qualitative input, in the patient's voice, regarding activities they would like to do but cannot do because of DMD, and reasons why these activities are important to them. Qualitative responses will be scored to provide quantitative frequency counts and point values for each answer dependent upon if the response was the most important, 2nd most important and 3rd most important activity to the participant. Data will be coded by two independent coders to ensure consistency. Scores will be calculated by functional category for:
Number of times each activity is mentioned
Overall score for each activity
Number of times each reason is mentioned
Overall score for each reason</description>
  </primary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Burden, Dependency</condition>
  <condition>Disability Physical</condition>
  <condition>Disease Management</condition>
  <condition>Impairment</condition>
  <condition>Rare Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be conducted in individuals 11 years or older living with Duchenne Muscular
        Dystrophy as well caregivers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant must be a person with DMD who is 11 years or older or The parent/legal
             guardian of a person with DMD who is under the age of 18 years.

          2. Confirmed diagnosis of DMD with written proof of disease provided

          3. Resident of the U.S.

          4. Able to read, write and communicate in English

          5. Able to grant informed consent

          6. Willing to participate in a 45 minute telephone interview

          7. Ability to view or receive a document from the interviewer before or during the
             interview (web browser, ability to receive a text, fax or document by mail)

        Exclusion Criteria:

        1. Inability to meet any of the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine McSherry, R.N.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jett Foundation, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Engage Health, Inc.</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.jettfoundation.org/</url>
    <description>Jett Foundation</description>
  </link>
  <reference>
    <citation>Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018 Mar;17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3. Review. Erratum in: Lancet Neurol. 2018 Apr 4;:.</citation>
    <PMID>29395989</PMID>
  </reference>
  <reference>
    <citation>Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018 Apr;17(4):347-361. doi: 10.1016/S1474-4422(18)30025-5. Epub 2018 Feb 3. Review.</citation>
    <PMID>29395990</PMID>
  </reference>
  <reference>
    <citation>Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, Cripe L, Herron AR, Kennedy A, Kinnett K, Naprawa J, Noritz G, Poysky J, Street N, Trout CJ, Weber DR, Ward LM; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018 May;17(5):445-455. doi: 10.1016/S1474-4422(18)30026-7. Epub 2018 Feb 2. Review.</citation>
    <PMID>29398641</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne, DMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Rare Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

